- The acute effects of microdosing psilocybin were reported to be more intense, but variability in subjective experiences was noted among participants.
- While unblinding may have influenced perceived effects, overall findings indicated no significant impact on cognitive functions and related measures.
- EEG results showed reduced theta band power associated with psilocybin microdosing, aligning with observations from studies using higher doses.
Introduction to Microdosing Psychedelics
In recent years, the practice of microdosing, defined as taking sub-hallucinogenic doses of psychedelics, has garnered significant attention for its potential cognitive and psychological benefits. Despite widespread anecdotal claims of enhanced creativity, mood elevation, and cognitive functioning associated with this practice, scientific understanding remains limited due to the scarcity of formal studies.
Study Design and Methodology
The researchers conducted a double-blind, placebo-controlled trial with 34 participants who were already considering microdosing with psilocybin mushrooms, specifically Psilocybe cubensis. Each participant received both an active dose (0.5g of dried mushrooms containing approximately 0.9mg of psilocybin) and a placebo during two separate sessions scheduled a week apart. To ensure scientific rigor, informed consent was secured, and the experimental design included various questionnaires to assess subjective effects, behavior, and cognitive performance, along with electroencephalogram (EEG) recordings to monitor brain activity.
Participant Recruitment and Ethical Approval
The participants for this study were recruited through various channels, including social media and workshops. They were required to be fluent in Spanish and received ethical approval for the research from the Universidad Abierta Interamericana in Buenos Aires. All individuals provided written informed consent prior to participation, emphasizing the study’s ethical integrity.
Experimental Framework
The experiment incorporated a within-subjects design, ensuring that participants experienced both the active and placebo conditions in random order. Participants completed a range of self-reported psychological scales before dosing to gauge expectations and personality traits. Following the dosing, the researchers analyzed the results across several cognitive and creativity tasks and utilized EEG technology to provide insights into the neurophysiological impacts of psilocybin microdosing.
Assessment Tools and Behavioral Tasks
The various self-reported scales included measures for anxiety, mood, stress, and cognitive flexibility. Additionally, participants engaged in creativity assessments to evaluate different aspects of creative thinking, including convergent and divergent thinking tasks. They also performed cognitive tasks that examined perception and attention to explore how microdosing influenced these cognitive processes.
Results and Findings
The outcomes demonstrated a significant difference in subjective experiences between the active and placebo doses, as participants reported higher scores on the Visual Analog Scale (VAS) for the microdose. However, this increase in reported intensity appeared inconsistent among individuals. Other measured outcomes, including cognitive tasks and behavioral assessments, yielded limited statistically significant results, indicating overall negligible effects on creativity, cognitive function, and self-reported well-being.
EEG Analysis and Cognitive Effects
In the EEG analysis, the researchers observed a reduction in theta band power when participants consumed the psilocybin microdose. This observation is consistent with previous studies using higher doses of psilocybin. While some cognitive tasks indicated minor trends toward impairment, the overall conclusion pointed to the lack of substantial impact from microdosing on cognitive performance.
Discussion on Microdosing Efficacies
Despite some participants reporting acute subjective effects, many outcomes did not demonstrate significant improvements across various domains. These findings challenge earlier anecdotal claims suggesting that microdosing can enhance cognition, well-being, and creativity. This reinforces the idea that expectancy effects might play a substantial role in the perceived benefits associated with microdosing practices.
Conclusion and Future Directions
The researchers’ study provides an essential contribution to the field of psychedelics by employing a well-controlled experimental design. While it observed significant subjective effects, the overall findings indicate that microdosing may not yield the anticipated benefits in creativity or cognition. Future research should aim to investigate longer-term effects of microdosing protocols and consider varying dosages and timing to enhance understanding of this burgeoning area of study.
Read the full paper summary on Blossom.
